Kyntra Bio Inc (NASDAQ:KYNB) Stock Has Average Price Target of $37.25

Shares of Kyntra Bio Inc (NASDAQ:KYNB) have been given an average recommendation of “Moderate Buy” by the six research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $37.25.

Several research firms recently commented on KYNB. Weiss Ratings raised Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, August 14th. HC Wainwright reaffirmed a “buy” rating and set a $43.00 price target on shares of Kyntra Bio in a report on Tuesday, September 1st. Rodman & Renshaw started coverage on Kyntra Bio in a research report on Tuesday, June 9th. They set a “buy” rating and a $30.00 price objective for the company. Oppenheimer began coverage on Kyntra Bio in a research report on Monday, July 6th. They set an “outperform” rating and a $35.00 target price on the stock. Finally, Lake Street Capital began coverage on Kyntra Bio in a research note on Thursday, September 17th. They set a “buy” rating and a $41.00 target price for the company.

Hedge Funds Weigh In On Kyntra Bio

A hedge fund recently bought a new position in Kyntra Bio stock. ADAR1 Capital Management LLC purchased a new position in shares of Kyntra Bio Inc (NASDAQ:KYNB) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned about 0.26% of Kyntra Bio at the end of the most recent reporting period. 72.71% of the stock is currently owned by institutional investors and hedge funds.

Kyntra Bio Price Performance

NASDAQ KYNB opened at $6.94 on Friday. The company has a market cap of $28.11 million, a P/E ratio of 0.15 and a beta of 1.06. The stock has a 50-day moving average of $7.43 and a two-hundred day moving average of $7.19. Kyntra Bio has a 1-year low of $6.32 and a 1-year high of $12.54.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.